Cancer Genetics Reports Third Quarter 2020 Financial Results
November 12, 2020 16:25 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced...
Cancer Genetics, Inc. Increases Previously Announced Bought Deal to $3.0 Million
October 28, 2020 21:55 ET
|
Cancer Genetics, Inc.
Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in drug discovery and preclinical oncology and immuno-oncology services,...
Cancer Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Strategic Business Updates
June 01, 2020 08:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., June 01, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced financial...
Cancer Genetics Issues Letter to Shareholders
February 20, 2020 09:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or the “Company”), a leader in drug discovery and preclinical oncology and immuno-oncology...
Cancer Genetics Announces 1-for-30 Reverse Stock Split
October 24, 2019 08:30 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it...